ESRRG and breast cancer: In summary, multiple breast cancer cell lines are preferentially growth-inhibited by the ERRβ/γ agonist DY131 as compared to a non-transformed breast epithelial cell line, and all express detectable levels of ERRβsf and ERRβ2 protein, whereas ERRγ protein expression is not consistently observed.